about
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infectionDistinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse modelVaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.Clonotypic composition of the CD4+ T cell response to a vectored retroviral antigen is determined by its speed.Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infectionImproved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypesCodelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytiaInduction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery.Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection.Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice.Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization.Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8+ T Cell Responses During Chronic Retroviral Infection.IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses.Effects of Friend Virus Infection and Regulatory T Cells on the Antigen Presentation Function of B CellsFcγ Receptor Type I (CD64)-Mediated Impairment of the Capacity of Dendritic Cells to Activate Specific CD8 T Cells by IgG-opsonized Friend VirusTransgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent mannerImmunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infectionComparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection ModelMMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance
P50
Q26748624-64CC9BAD-B99E-439B-825E-159EFC115DE1Q27003380-BE8ECCC2-1E86-485F-9F28-C20CF45998B1Q33614622-90AE79A3-D6CC-4928-BA16-2D1F69A5858CQ33993393-B9ED3D14-E9E6-4664-990A-391BD620DC9EQ35070346-DA7E77AA-C15E-4482-BCDB-F37230F625E7Q35353052-0D3A779B-CD3E-46B6-84F2-A5A5659081E5Q35689651-677CD009-C5B5-4836-8419-6164C80B50B8Q37240366-662BBA51-D7C3-44EA-BF15-BBD328E059FFQ37628079-51FDC366-EC43-44E8-A2F2-59CFF17747B8Q38976254-C9280A8E-13B8-4C0D-8132-2FC8770F1004Q40212928-6684FB81-C7F6-46EA-80EA-9B2FDF18DDF1Q40264235-838B1384-D39A-4A4C-B147-873CBAA0C909Q41574561-8959A987-7BD2-4A3A-8590-FB1337995009Q43446809-1C336B5B-F069-440C-A53B-422F0CC4CCD5Q54217623-A303D947-FA9F-427C-904B-BFDD8AF5BB71Q54255052-2543780F-6308-4792-9900-9682A4FB7243Q61445480-0F8F77DD-58E8-4397-A9DE-B396B2B052F7Q64252983-70F02CA7-5348-4D05-8FA3-3F0B1BCA8DC3Q64375110-5C631620-BF8D-48FE-9E66-FD810728612DQ90375083-8ED2658D-6BA2-4D7E-BA95-4C07356EBC29Q92376584-5EE92FDE-C91D-40D5-8264-4DB86EAC0B2CQ92586053-5761A05A-9FE0-4B21-9D65-5ACF0BBB64CC
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Wibke Bayer
@en
Wibke Bayer
@nl
type
label
Wibke Bayer
@en
Wibke Bayer
@nl
altLabel
Bayer W
@en
prefLabel
Wibke Bayer
@en
Wibke Bayer
@nl
P31
P496
0000-0002-5885-5592